title: Manganese superoxide dismutase in healthy human pleural mesothelium and in malignant pleural mesothelioma.
abstract: We hypothesized that manganese superoxide dismutase (MnSOD), known to be induced in rat mesothelial cells by asbestos fibers, cytokines, and hyperoxia, may also be induced in asbestos-related pleural diseases such as mesothelioma. MnSOD was assessed in healthy human pleural mesothelium (n = 6), in biopsy samples of human pleural mesothelioma (n = 7), in transformed nonmalignant human mesothelial cells (Met5A), and in two human mesothelioma cell lines (M14K and M38K) established from the tumor tissue of mesothelioma patients. There was no MnSOD immunoreactivity in five of the six samples of healthy pleural mesothelium, whereas MnSOD immunoreactivity was high in the tumor cells in all the mesothelioma samples. Northern blotting, immunohistochemistry, Western blotting, and specific activity measurements showed lower MnSOD in the nonmalignant Met5A mesothelial cells than in the M14K and M38K mesothelioma cells. In additional experiments the mesothelial and mesothelioma cells were exposed to menadione, which generates superoxide intracellularly, and to epirubicin, a cytotoxic drug commonly used to treat mesothelioma. The M38K mesothelioma cells were most resistant to menadione and epirubicin when assessed by LDH release or by adenine nucleotide (ATP, ADP, and AMP) depletion. These same cells showed not only the highest MnSOD levels, but also the highest mRNA levels and activities of catalase, whereas glutathione peroxidase and glutathione reductase levels did not differ significantly. We conclude that MnSOD expression is low in healthy human pleural mesothelium and high in human malignant mesothelioma. The most resistant mesothelioma cells contained coordinated induction of MnSOD and catalase.
authors.affiliation: Department of Internal Medicine, University of Oulu, Oulu, Finland.
authors.forename: K
authors.initials: K
authors.lastname: Kahlos
authors.forename: S
authors.initials: S
authors.lastname: Anttila
authors.forename: T
authors.initials: T
authors.lastname: Asikainen
authors.forename: K
authors.initials: K
authors.lastname: Kinnula
authors.forename: K O
authors.initials: KO
authors.lastname: Raivio
authors.forename: K
authors.initials: K
authors.lastname: Mattson
authors.forename: K
authors.initials: K
authors.lastname: Linnainmaa
authors.forename: V L
authors.initials: VL
authors.lastname: Kinnula
mesh_terms: D000328:Adult; D000368:Aged; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage / Q000633:toxicity; D000975:Antioxidants / Q000378:metabolism; D001706:Biopsy; D002461:Cell Line, Transformed; D015251:Epirubicin / Q000008:administration & dosage / Q000633:toxicity; D004847:Epithelial Cells / Q000187:drug effects / Q000201:enzymology*; D016166:Free Radical Scavengers / Q000378:metabolism; D006490:Hemostatics / Q000008:administration & dosage / Q000633:toxicity; D006801:Humans; D006861:Hydrogen Peroxide / Q000378:metabolism; D008297:Male; D008654:Mesothelioma / Q000201:enzymology*; D008875:Middle Aged; D010994:Pleura / Q000166:cytology* / Q000201:enzymology / Q000473:pathology; D010997:Pleural Neoplasms / Q000201:enzymology* / Q000473:pathology; D013482:Superoxide Dismutase / Q000187:drug effects / Q000378:metabolism*; D014407:Tumor Cells, Cultured; D014812:Vitamin K / Q000008:administration & dosage / Q000633:toxicity
chemical_list: D000903:Antibiotics, Antineoplastic; D000975:Antioxidants; D016166:Free Radical Scavengers; D006490:Hemostatics; D014812:Vitamin K; D015251:Epirubicin; D006861:Hydrogen Peroxide; D013482:Superoxide Dismutase